<DOC>
	<DOCNO>NCT03029000</DOCNO>
	<brief_summary>A , multi-center , open-label , single-arm clinical study assess effect 5-day regimen 10 Î¼g/kg tbo-filgrastim administer sc daily mobilization CD34+ cell least 60 healthy male female donor . The pharmacokinetics , pharmacodynamics , safety , tolerability , immunogenicity tbo-filgrastim assess .</brief_summary>
	<brief_title>Study Effect 5-day Regimen Study Drug Peripheral Stem Cell Mobilization Healthy Donors</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>The donor BW 50 120 kg , inclusive . The donor BMI 18.5 less 30.0 kg/m2 . The donor good health Additional criterion apply , please contact investigator information The donor currently history clinically relevant gastrointestinal , hematologic , respiratory , psychiatric , renal , hepatic , cardiac , metabolic ( eg , fructose intolerance ) , neurological , disease condition may influence physiological metabolic turnover ( eg , severe endocrine disease , febrile condition , severe infection The donor : ( 1 ) trauma surgery past 2 month The donor existence recent history persistent pulmonary infiltrates , recent pneumonia , recent bronchitis , recurrent lung infection , history evidence lung disease include asthma , current symptom upper respiratory tract infection The donor history malignancy , include hematologic malignancy , except appropriately treat nonmelanoma skin carcinoma last 5 year . The donor pregnant lactating , pregnant previous 6 month , intend get pregnant study within 30 day last dose study drug The donor donate plasma within 7 day screen donated blood within 56 day screen . The donor document selfreported history tuberculosis recent travel country endemic disease ( last 8 week ) Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>